The Latest Breaking News from Novo Nordisk

Ministers have announced plans which could see tens of thousands given access to new weight-loss drug

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

In today’s newsletter: Semaglutide has won endorsements from celebrities and expert drugs advisers and has gone viral on TikTok. But don’t expect a quick fix

Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year.

Balanced diet and exercise remain key to losing weight, health body says

New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.

Novo Nordisk stock slumped Thursday after its weight loss blockbuster, Wegovy, missed sales expectations despite rocketing demand.

Drug shortages are growing in the United States, and experts see no clear path to resolving them

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes